View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter’s Weekly Newsletter
John Kastelein is a renowned expert in lipoprotein metabolism and atherosclerotic cardiovascular disease (ASCVD) research. In this discussion, John delves deep into familial hypercholesterolemia (FH), a genetic disorder characterized by high levels of LDL cholesterol in the blood that increases the risk of developing heart disease. He covers its definition, genetic underpinnings, and clinical identification. He then explores the therapeutic options available for the prevention and treatment of cardiovascular disease, including the captivating history of CETP inhibitors. He explains the past shortcomings of previous CETP inhibitors before underscoring the compelling potential of the latest iterations, not only for cardiovascular disease but also for conditions like Alzheimer's disease and type 2 diabetes. Moreover, he unveils the intricate role of APOE, shedding light on why the APOE4 isoform codes for a protein that significantly increases the risk of Alzheimer's disease and cardiovascular disease. Concluding the discussion, John shares a profound sense of optimism, envisioning the possibility of targeted therapeutic interventions for high-risk patients in the near future.
We discuss:
Connect With Peter on Twitter, Instagram, Facebook and YouTube
#195 - Freedom, PTSD, war, and life through an evolutionary lens | Sebastian Junger
#194 - How fructose drives metabolic disease | Rick Johnson, M.D.
#193 - AMA #31: Heart rate variability (HRV), alcohol, sleep, and more
#192 - COVID Part 2: Masks, long COVID, boosters, mandates, treatments, and more
#191 - Revolutionizing our understanding of mental illness with optogenetics | Karl Deisseroth M.D., Ph.D.
#190 - Paul Conti, M.D.: How to heal from trauma and break the cycle of shame
#189 - COVID-19: Current state of affairs, Omicron, and a search for the end game
Iñigo San Millán, Ph.D.: Zone 2 Training and Metabolic Health (Ep. #85 Rebroadcast)
#188 - AMA #30: How to Read and Understand Scientific Studies
#187 - Sam Apple: The Warburg Effect—Otto Warburg’s cancer metabolism theory
#186 - Patrick Radden Keefe: The opioid crisis—origin, guilty parties, and the difficult path forward
#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
Rick Johnson, M.D.: Metabolic Effects of Fructose (Ep. #87 Rebroadcast)
#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?
#183 - James Clear: Building & changing habits
#182 - David Nutt: Psychedelics & Recreational Drugs
#181 - Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
#180 - AMA #28: All things testosterone and testosterone replacement therapy
#179 - Jeremy Loenneke, Ph.D.: The science of blood flow restriction—benefits, uses, and what it teaches us about the relationship between muscle size and strength
#178 - Lance Armstrong: The rise, fall, and growth of a cycling legend
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Huberman Lab
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.